Washington Trust Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Washington Trust Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$116	Sell	82 -78	-49%	-$91	﹤0.01%	723
2026 Q1	$214	Hold	160	–	–	﹤0.01%	683
2025 Q4	$256	Hold	160	–	–	﹤0.01%	584
2025 Q3	$410	Hold	160	–	–	﹤0.01%	684
2025 Q2	$290	Hold	160	–	–	﹤0.01%	631
2025 Q1	$325	Sell	160 -1	-0.6%	-$4	﹤0.01%	636
2024 Q4	$962	Hold	161	–	–	﹤0.01%	639
2024 Q3	$1.57K	Hold	161	–	–	﹤0.01%	645
2024 Q2	$3.29K	Hold	161	–	–	﹤0.01%	605
2024 Q1	$7.25K	Hold	161	–	–	﹤0.01%	524
2023 Q4	$7.59K	Buy	161 +83	+106%	+$4.61K	﹤0.01%	519
2023 Q3	$3.16K	Hold	78	–	–	﹤0.01%	604
2023 Q2	$8.32K	Hold	78	–	–	﹤0.01%	485
2023 Q1	$23.3K	Hold	78	–	–	﹤0.01%	398
2022 Q4	$26.9K	Hold	78	–	–	﹤0.01%	383
2022 Q3	$15K	Hold	78	–	–	﹤0.01%	546
2022 Q2	$16K	Buy	78 +62	+388%	+$13K	﹤0.01%	569
2022 Q1	$5K	Hold	16	–	–	﹤0.01%	812
2021 Q4	$5K	Buy	+16	New	+$6.87K	﹤0.01%	842

Other funds holding BTAI

DWM

Diversify Wealth Management Sandy, Utah $5.98B AUM 29.21% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

TCM

Triumph Capital Management Denver, Colorado $552M AUM 20.75% 1-Year Est. Return

Washington Trust Advisors's BTAI Position: Q2 2026 in Review

Washington Trust Advisors reduced its BioXcel Therapeutics (BTAI) stake by 49% in Q2 2026, selling an estimated $91 and leaving 82 shares worth $116. The position accounts for ﹤0.01% of the portfolio, ranked #723.

Washington Trust Advisors first reported a position in BTAI in Q4 2021 and has held it in 19 quarters since. The position peaked at $26.9K in Q4 2022. 8 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

Washington Trust Advisors held 82 shares of BioXcel Therapeutics worth $116 as of Q2 2026.
Washington Trust Advisors sold 78 BioXcel Therapeutics shares in Q2 2026, an estimated $91.
BioXcel Therapeutics made up ﹤0.01% of Washington Trust Advisors's portfolio in Q2 2026, its #723 holding.
Washington Trust Advisors first reported a position in BioXcel Therapeutics in Q4 2021 and has held it in 19 quarters since.
Washington Trust Advisors's BioXcel Therapeutics position peaked at $26.9K in Q4 2022.
8 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Washington Trust Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.